Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) Meeting Abstract
| Authors: | Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; Orloff, M.; Evans, J.; Edukulla, R.; Holland, C.; Abdullah, S.; Mundy, R.; Middleton, M. |
| Abstract Title: | Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) |
| Meeting Title: | 36th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2021) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 9 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Nov 10-14 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-11-01 |
| Start Page: | A576 |
| Language: | English |
| ACCESSION: | WOS:000774877500523 |
| DOI: | 10.1136/jitc-2021-SITC2021.546 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 546 -- Meeting was also held virtually -- Source: Wos |
